• Key Roles to Support both Technology and Business Evolvement
    Catherine Beech OBE
  • Benedict Cross

News & Views

Key Roles to Support both Technology and Business Evolvement

Feb 26 2020

Biopharmaceutical company Phoremost has announced the appointments of Dr Catherine Beech as Non-Executive Director and Dr Benedict (Ben) Cross, who has joined as Senior Director (Technology), with responsibility for directing the evolution and development of the Company’s screening platform.

Catherine has over 25 years of biotech and pharmaceutical industry experience, including leading drug development programmes in hypertension, heart failure, Parkinson’s disease and HIV. She has also worked extensively to commercialise novel technologies in the life sciences and is a scientific founder and CEO of Exonate. Catherine has a degree in medicine from the University of Birmingham and in 2008 was awarded an OBE for services to technology and innovation.

Ben is a geneticist and biotechnologist with over ten years of professional research and management experience. He joins the company from Horizon Discovery, where he established and led the company’s functional genomic screening platform over a period of six years. The screening group now executes hundreds of screens per year, generating multi-million-pound revenue. Ben completed his PhD at the University of Manchester, with postdoctoral training at the University of Cambridge.

Dr Chris Torrance, CEO, PhoreMost, said: “We welcome both Ben and Catherine to the PhoreMost team at this exciting point in the Company’s development. We very much look forward to working with Ben to maximise the potential of the SITESEEKER platform and to the addition of Catherine’s valuable experience and guidance on the Board of Directors.”

Dr Catherine Beech, OBE, Non-Executive Director, PhoreMost, said: “I am absolutely delighted to join the Board of PhoreMost. I believe the Company is poised for success, and that 2020 will be a tremendous year on many fronts.”

Dr Ben Cross Senior Director (Technology), PhoreMost, commented: “I am excited to have been given this opportunity to work with PhoreMost and the SITESEEKER platform, which has huge potential to uncover not only previously undruggable targets, but also druggable pockets within those targets. I am very much looking forward to working with the team to drive this forward.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Handling - Clinical, Medical & Diagnostic Products News...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events